Search

everythinglearnresearchcommunity

for

Search:↓

5-alpha reductase inhibitors increase the risk of sexual dysfunction in patients treating enlarged prostate but not in those treating hair loss.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

Pregnancy causes skin changes like darkening, hair thickening, nail changes, and increased risk of skin growths, most of which usually resolve after birth.

Long-term testosterone therapy can cause hormone suppression, affect prostate and heart health, and alter physical characteristics, but does not increase prostate cancer risk and needs more research for full risk assessment.

Dihydrotestosterone has a reduced effect on muscle-building in people with testicular feminization syndrome, especially after their gonads are removed.

5-alpha reductase inhibitors can cause sexual side effects like erectile dysfunction and reduced sexual desire, sometimes lasting after stopping the drug.

Dutasteride can reduce night-time urination but it doesn't improve sleep quality.

A new method using a Foley catheter on a ureteroscope makes difficult urethral catheterization easier and more effective.

Pregnancy can cause skin darkening, varicose veins, more sweating, hair growth, hair loss after birth, nail changes, and gum inflammation.

Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.

After menopause, some women lose scalp hair and gain facial hair, with patterns suggesting different underlying causes.

Hormone therapy for prostate cancer can increase heart risks, especially in men with heart conditions.

The 2024 guideline updates recommendations for genetic testing, imaging, and sperm retrieval in male infertility.

5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.

Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.

The document concludes that antiandrogenic drugs like cyproterone acetate and spironolactone are effective but not permanent treatments for skin-related androgenization in women.

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

A postmenopausal woman's virilization was caused by a rare ovarian tumor that was hard to detect but was successfully treated with surgery.

Hormonal changes after childbirth and menopause can lead to women's hair loss and facial hair growth, with a need for better treatments.

Hormonal therapy for transgender individuals carries health risks but is a personal choice.

Finasteride and DEHP exposure during development can change reproductive markers in rats.

Pre-operative hormone treatment for hypospadias surgery might improve outcomes, but more research is needed to confirm.

Prenatal antiandrogen treatment altered hormone levels in adult spotted hyenas, affecting males and females differently.

Hormone therapy for transgender females increases the risk of blood clots and requires careful dosing, monitoring, and lifelong management.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.

Lower adrenal hormone levels may cause hair loss in postmenopausal women, certain patterns help diagnose nail cancer, and a gene variant linked to higher skin cancer risk in kidney transplant patients suggests monitoring folate levels.

Finasteride treatment increased blood volume and reduced vessel leakiness in beagle prostates.

Skin problems are common in kidney disease, with dry skin and itching in patients not on dialysis or on hemodialysis, and infections most common in transplant recipients.